Elanco Animal Health Incorporated (NYSE:ELAN) Shares Purchased by Bfsg LLC

Bfsg LLC grew its position in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 41.4% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 24,554 shares of the company’s stock after acquiring an additional 7,191 shares during the quarter. Bfsg LLC’s holdings in Elanco Animal Health were worth $297,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Truist Financial Corp increased its stake in Elanco Animal Health by 173.1% during the fourth quarter. Truist Financial Corp now owns 190,284 shares of the company’s stock worth $2,304,000 after acquiring an additional 120,596 shares during the last quarter. DDD Partners LLC purchased a new stake in shares of Elanco Animal Health in the fourth quarter worth about $5,974,000. Rhumbline Advisers boosted its position in shares of Elanco Animal Health by 0.5% in the fourth quarter. Rhumbline Advisers now owns 481,438 shares of the company’s stock worth $5,830,000 after buying an additional 2,209 shares during the period. Blue Trust Inc. boosted its position in shares of Elanco Animal Health by 47.7% in the fourth quarter. Blue Trust Inc. now owns 5,862 shares of the company’s stock worth $71,000 after buying an additional 1,894 shares during the period. Finally, MTM Investment Management LLC boosted its position in shares of Elanco Animal Health by 9.3% in the fourth quarter. MTM Investment Management LLC now owns 14,168 shares of the company’s stock worth $172,000 after buying an additional 1,200 shares during the period. 97.48% of the stock is currently owned by institutional investors and hedge funds.

Elanco Animal Health Trading Up 0.6 %

NYSE:ELAN opened at $11.32 on Wednesday. The company has a quick ratio of 1.31, a current ratio of 2.55 and a debt-to-equity ratio of 0.66. The business’s 50 day moving average is $11.88 and its two-hundred day moving average is $13.13. Elanco Animal Health Incorporated has a 52 week low of $10.77 and a 52 week high of $18.80. The company has a market cap of $5.59 billion, a PE ratio of 28.29, a P/E/G ratio of 2.69 and a beta of 1.42.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on ELAN. Morgan Stanley decreased their target price on Elanco Animal Health from $15.00 to $14.00 and set an “equal weight” rating for the company in a research report on Wednesday, January 29th. Barclays increased their price target on Elanco Animal Health from $19.00 to $20.00 and gave the company an “overweight” rating in a report on Friday, November 8th. UBS Group assumed coverage on Elanco Animal Health in a report on Monday, December 9th. They issued a “buy” rating and a $18.00 price target for the company. Stifel Nicolaus reduced their price target on Elanco Animal Health from $20.00 to $18.00 and set a “buy” rating for the company in a report on Tuesday, January 7th. Finally, Leerink Partners assumed coverage on Elanco Animal Health in a report on Monday, December 2nd. They issued a “market perform” rating and a $14.00 price target for the company. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat.com, Elanco Animal Health currently has a consensus rating of “Hold” and an average price target of $16.29.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.